CD19 and diffuse large B-cell lymphoma: The manufacture of the currently approved commercial CAR-T cell products consists of using genetically engineered autologous lymphocytes that have been modified to harbor a T-cell receptor that recognizes a specific antigen, most commonly the CD19 antigen—a key antigen expressed on DLBCL and B-cell acute lymphoblastic leukemia (B-ALL).